U.S. FDA extends review of Humacyte blood vessel implant
Humacyte U.S. health regulator said it has expanded the company’s authority to test an implant that can replace a damaged or injured blood vessel, causing its shares to fall more than 15% after the close of trading.
ENTRADAS POPULARES
UK sets new climate target for 2035
noviembre 13, 2024
Children go back to school after Valencia floods
noviembre 13, 2024
Researchers document huge decline in African elephants
noviembre 13, 2024
Mission: Impossible 8 title revealed
noviembre 13, 2024
TRANSMISIÓN EN VIVO